Literature DB >> 10993717

Human acid ceramidase gene: novel mutations in Farber disease.

Z Zhang1, A K Mandal, A Mital, N Popescu, D Zimonjic, A Moser, H Moser, A B Mukherjee.   

Abstract

Farber disease is an autosomal recessive disorder caused by lysosomal acid ceramidase (AC) deficiency. It commonly manifests during the first few months after birth with a unique triad of painful and progressive deformed joints, subcutaneous nodules, and progressive hoarseness. In order to understand the molecular mechanism(s) of pathogenesis of Farber disease, we isolated and characterized a full-length human AC gene, mapped its chromosomal location, determined the tissue-specific expression, and analyzed mutations in Farber disease patients. We also studied the AC-mRNA expression in gastrointestinal tumors and adjoining normal tissues. In addition, we determined the pattern of tissue-specific AC-mRNA expression in the adult mouse and during fetal development. Our results show that human AC gene consists of 14 exons and 13 introns spanning approximately 26.5 kb of genomic DNA. It is mapped to human chromosome 8p22-21.2, a region often disrupted in several cancers. The AC-mRNA is expressed in the mouse fetus from the seventh day of gestation. Interestingly, while the AC-mRNA is expressed in all segments of the normal gastrointestinal tract, none of the gastrointestinal tumor tissues had any AC-mRNA expression. We also uncovered four novel mutations in Farber disease patients that were not previously reported. Taken together, our results not only attest to the physiological importance of AC but also uncover several new mutations in Farber disease that may advance our knowledge towards establishing a genotype-phenotype correlation in this disease. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993717     DOI: 10.1006/mgme.2000.3029

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

1.  Analyses of temporal regulatory elements of the prosaposin gene in transgenic mice.

Authors:  Ying Sun; David P Witte; Peng Jin; Gregory A Grabowski
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

2.  Accumulation of ordered ceramide-cholesterol domains in farber disease fibroblasts.

Authors:  Natalia Santos Ferreira; Michal Goldschmidt-Arzi; Helena Sabanay; Judith Storch; Thierry Levade; Maria Gil Ribeiro; Lia Addadi; Anthony H Futerman
Journal:  JIMD Rep       Date:  2013-07-12

3.  Farber lipogranulomatosis: clinical and molecular genetic analysis reveals a novel mutation in an Indian family.

Authors:  Akela Radha Rama Devi; Munimanda Gopikrishna; Raman Ratheesh; Gorinabele Savithri; Gowrishankar Swarnalata; Murali Bashyam
Journal:  J Hum Genet       Date:  2006-09-02       Impact factor: 3.172

Review 4.  Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate.

Authors:  Cungui Mao; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2008-06-13

5.  Mutation analysis of the acid ceramidase gene in Japanese patients with Farber disease.

Authors:  T Muramatsu; N Sakai; I Yanagihara; M Yamada; T Nishigaki; C Kokubu; H Tsukamoto; M Ito; K Inui
Journal:  J Inherit Metab Dis       Date:  2002-11       Impact factor: 4.982

Review 6.  Acid ceramidase deficiency: Farber disease and SMA-PME.

Authors:  Fabian P S Yu; Samuel Amintas; Thierry Levade; Jeffrey A Medin
Journal:  Orphanet J Rare Dis       Date:  2018-07-20       Impact factor: 4.123

7.  Systemic ceramide accumulation leads to severe and varied pathological consequences.

Authors:  Abdulfatah M Alayoubi; James C M Wang; Bryan C Y Au; Stéphane Carpentier; Virginie Garcia; Shaalee Dworski; Samah El-Ghamrasni; Kevin N Kirouac; Mathilde J Exertier; Zi Jian Xiong; Gilbert G Privé; Calogera M Simonaro; Josefina Casas; Gemma Fabrias; Edward H Schuchman; Patricia V Turner; Razqallah Hakem; Thierry Levade; Jeffrey A Medin
Journal:  EMBO Mol Med       Date:  2013-05-16       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.